The results were similar in the KR158 glioma model except for the CED-TMZ monotherapy, where there was no difference compared to non-treated (CD8+/mm2: CED-TMZ + KR158 vs. non-treated: p = 0.0022; KR158 vs. non-treated: p = 0.022. Here, CD8A is linked to glioma.